{"title":"接受纳武单抗联合化疗的晚期胃癌患者免疫相关不良事件与治疗结果之间的关联：一项回顾性研究","authors":"Kazumasa Yamamoto, Hidekazu Hirano, Toshiharu Hirose, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Ken Kato","doi":"10.1002/cam4.71252","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Immune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed clinical data from patients with HER2-negative AGC who received first-line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression-free survival (PFS), were compared using Kaplan–Meier analysis, landmark analysis, and Cox proportional hazards regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade ≥ 3 irAEs. Patients with irAEs had significantly longer OS and PFS in comparison to those without irAEs (median OS: not reached vs. 17.1 months, <i>p</i> < 0.01; median PFS: not reached vs. 6.8 months, <i>p</i> < 0.01). Multivariate analysis identified the occurrence of irAEs as a favorable prognostic factor for OS (hazard ratio: 0.13; 95% CI: 0.03–0.59; <i>p</i> < 0.01).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study suggests that the occurrence of irAEs is associated with improved survival outcomes in patients with AGC receiving chemotherapy plus nivolumab. IrAEs may serve as a predictive marker for treatment response in this setting.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441737/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study\",\"authors\":\"Kazumasa Yamamoto, Hidekazu Hirano, Toshiharu Hirose, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Ken Kato\",\"doi\":\"10.1002/cam4.71252\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Immune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This retrospective study analyzed clinical data from patients with HER2-negative AGC who received first-line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression-free survival (PFS), were compared using Kaplan–Meier analysis, landmark analysis, and Cox proportional hazards regression.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade ≥ 3 irAEs. Patients with irAEs had significantly longer OS and PFS in comparison to those without irAEs (median OS: not reached vs. 17.1 months, <i>p</i> < 0.01; median PFS: not reached vs. 6.8 months, <i>p</i> < 0.01). Multivariate analysis identified the occurrence of irAEs as a favorable prognostic factor for OS (hazard ratio: 0.13; 95% CI: 0.03–0.59; <i>p</i> < 0.01).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study suggests that the occurrence of irAEs is associated with improved survival outcomes in patients with AGC receiving chemotherapy plus nivolumab. IrAEs may serve as a predictive marker for treatment response in this setting.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 18\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441737/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71252\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71252","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study
Background
Immune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.
Methods
This retrospective study analyzed clinical data from patients with HER2-negative AGC who received first-line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression-free survival (PFS), were compared using Kaplan–Meier analysis, landmark analysis, and Cox proportional hazards regression.
Results
Among the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade ≥ 3 irAEs. Patients with irAEs had significantly longer OS and PFS in comparison to those without irAEs (median OS: not reached vs. 17.1 months, p < 0.01; median PFS: not reached vs. 6.8 months, p < 0.01). Multivariate analysis identified the occurrence of irAEs as a favorable prognostic factor for OS (hazard ratio: 0.13; 95% CI: 0.03–0.59; p < 0.01).
Conclusion
This study suggests that the occurrence of irAEs is associated with improved survival outcomes in patients with AGC receiving chemotherapy plus nivolumab. IrAEs may serve as a predictive marker for treatment response in this setting.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
